WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience
QUICK SEARCH:   [advanced]


     
-


HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (92)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tepper, J. M.
Right arrow Articles by Creese, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tepper, J. M.
Right arrow Articles by Creese, I.

 Previous Article  |  Next Article 

Volume 17, Number 7, Issue of April 1, 1997 pp. 2519-2530
Copyright ©1997 Society for Neuroscience

Functional Roles of Dopamine D2 and D3 Autoreceptors on Nigrostriatal Neurons Analyzed by Antisense Knockdown In Vivo

James M. Tepper, Bao-Cun Sun, Lynn P. Martin, and Ian Creese

Center for Molecular and Behavioral Neuroscience, Aidekman Research Center, Program in Cellular and Molecular Biodynamics, Rutgers, The State University of New Jersey, Newark, New Jersey 07102

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES

ABSTRACT

Two different 19-mer antisense oligodeoxynucleotides complementary to the initial coding regions of dopamine D2 or D3 receptor mRNA were infused unilaterally into the substantia nigra of rats for 3-6 d to suppress synthesis of D2 and/or D3 receptors on substantia nigra dopaminergic neurons, thereby producing specific reductions of D2 and/or D3 receptors. Autoradiographic receptor binding revealed that D2 and D3 antisense oligodeoxynucleotides specifically and significantly reduced D2 or D3 binding in the ipsilateral substantia nigra, respectively, without affecting dopamine receptor binding in the neostriatum. Either D2 or D3 antisense oligodeoxynucleotides greatly attenuated the ability of apomorphine to inhibit dopaminergic neurons in vivo, an effect that was potentiated by simultaneous administration of D2 and D3 antisenses. Despite these effects, neither the rate nor the pattern of spontaneous activity of antisense-treated nigrostriatal neurons differed from those in the control groups. The proportion of antidromic responses consisting of full spikes from antisense-treated rats was significantly greater, and the mean antidromic threshold was significantly lower than in controls, indicating that autoreceptor knockdown increased both somatodendritic and terminal excitability. These data demonstrate that selective reduction of specific dopamine receptor subtypes by antisense infusion can be effected in vivo, and that nigrostriatal neurons express both D2 and D3 autoreceptors at their somatodendritic and axon terminal regions. Although the somatodendritic and terminal autoreceptors modulate dendritic and terminal excitability, respectively, the interaction of endogenously released dopamine with somatodendritic autoreceptors does not appear to exert a significant effect on spontaneous activity in anesthetized rats.

Key words: antisense oligodeoxynucleotide; autoreceptor; dopamine receptor subtype; D2 receptor; D3 receptor; electrophysiology; substantia nigra

INTRODUCTION

Mesencephalic dopaminergic neurons express receptors for their own neurotransmitter, dopamine (DA), in their somatodendritic and axon terminal regions. Stimulation of somatodendritic autoreceptors inhibits the spontaneous activity of dopaminergic neurons (Bunney et al., 1973; Groves et al., 1975), whereas stimulation of the axon terminal autoreceptors reduces the excitability of DAergic axon terminals and inhibits DA synthesis and release (Tepper et al., 1987; Starke et al., 1989; Wolf and Roth, 1990).

DA receptors were originally classified as D1 or D2 receptors based on their differing affinities for various ligands and linkage to intracellular signaling pathways (Kebabian and Calne, 1979). Within this classification, the somatodendritic autoreceptor was identified as a D2 receptor on pharmacological (Morelli et al., 1988), electrophysiological (Lacey et al., 1987), and molecular biological (Meador-Woodruff et al., 1991) grounds. The axon terminal autoreceptor was similarly identified as a D2 receptor pharmacologically (Boyar and Altar, 1987; Starke et al., 1989) and electrophysiologically (Tepper et al., 1984a,b).

However, advances in molecular biology have rendered this "identification" uncertain, because it is now clear that two families of DA receptors exist (Sibley and Monsma, 1992). The D1-class family consists of D1 and D5 receptors and the D2-class family of D2L or S isoforms and D3 and D4 receptors. (Nonsubscripted receptor subtypes, e.g., D1-class, refer to the receptor family, whereas subscripted receptor subtypes, e.g., D2, refer to the molecular biologically defined specific receptor subtypes.)

Relatively large amounts of D2 mRNA exist in the midbrain, localized to dopaminergic neurons; however, the existence of D3 receptors in midbrain is more controversial. Some studies report D3 mRNA in the substantia nigra-ventral tegmental area (Sokoloff et al., 1990; Bouthenet et al., 1991), whereas others failed to find D3 mRNA or found it only in trace amounts (Valerio et al., 1994; Diaz et al., 1995; Le Moine and Bloch, 1996). On the other hand, it has recently been argued on pharmacological grounds that some DA autoreceptors may, in fact, be D3 receptors (Meller et al., 1993; Tang et al., 1994; Chesi et al., 1995; Kreiss et al., 1995; Lejeune and Millan, 1995; Nissbrandt et al., 1995). Because the KDs for most agonists and antagonists are within one order of magnitude between D2 and D3 receptors (Gingrich and Caron, 1993; Seeman and Van Tol, 1994; Burris et al., 1995), they cannot be used to discriminate, at least in a physiologically useful manner, among members within the D2-class family. Thus, the precise subtype(s) of the somatodendritic and terminal autoreceptors remains unknown.

Antisense knockdown refers to the ability of specifically designed short sequences of oligodeoxynucleotides to bind to their complementary mRNA and stop translation, thereby preventing the expression of the protein that the mRNA codes for. It is highly specific, and can be used to probe the functions of receptor subtypes for which specific and selective agonists or antagonists do not exist (Zhang and Creese, 1993). Here we describe the electrophysiological consequences of antisense knockdown of DA D2, and/or D3 receptors in DAergic nigrostriatal neurons.

MATERIALS AND METHODS

Subjects. Eighty-three male Harlan Sprague Dawley rats (Zivic-Miller) weighing between 150 and 250 gm at the time of initial surgery were used in these experiments. All animals were treated in strict accordance with guidelines set forth in the Public Health Service manual "Guide for the Care and Use of Laboratory Animals."

Antisense treatment. Rats were anesthetized with a mixture of ketamine (80 mg/kg) and xylazine (15 mg/kg) intraperitoneally and placed in a stereotaxic apparatus. Under aseptic conditions, the scalp was reflected and a small burr hole was drilled overlying the left substantia nigra [anterior: 2.0 (from lambda); lateral: 4.7 (at a 20° angle; see below)]. A 28 ga stainless steel infusion guide cannula (Plastics One, Roanoke, VA) was lowered 5.9 mm from the cortical surface and affixed with cyanoacrylate glue and dental cement. After a 24 hr recovery period, the inner 33 ga injection cannula, which was 1 mm longer than the guide, was filled, inserted into the guide, and connected to a length of Teflon tubing connected through an Instech Lab fluid swivel to a Harvard Apparatus Model digital 22 syringe pump. To minimize mechanical damage to the pars compacta, the nigral cannula was inserted at an angle of 20° to the midline such that the tip of the inner cannula was positioned ~500 µm dorsal and lateral to the center of the pars compacta. Oligodeoxynucleotides (10-20 µg/µl) or saline vehicle were infused continuously at 0.1 µl/hr for 3-6 d while the animals were housed in individual circular Plexiglas cages with access to food and water ad libitum. During the course of the antisense treatment, some animals were observed for two 30 min periods each day (at approximately 10:00 A.M. and 7:00 P.M.), and rotational behavior was recorded manually. A rotation was scored when a rat traversed 360° in either direction, and the total number of rotations was calculated by subtracting the number of ipsilateral rotations from the number of contralateral rotations that occurred during both 30 min periods.

Antisense oligodeoxynucleotides. The D2 antisense oligodeoxynucleotide (AODN) was a 19-mer complementary to codons 2-8 (nucleotides 4-22) of the D2 receptor mRNA with sequence 5'-AGGACAGGTTCAGTGGATC-3'. The D3 AODN, also directed against codons 2-8 (nucleotides 4-22), had the sequence 5'-TTATCTGGCTCAGAGGTGC-3'. There were two AODN controls: a D2 random AODN consisted of the same bases as in the D2 AODN in pseudorandom order with 11 of the 19 bases mismatched from the sense mRNA (5'-AGAACGGCACTTAGTGGGT-3') and a D3 random oligodeoxynucleotide that consisted of the same bases as in the D3 antisense AODN but with 14 bases mismatched (5'-ATTCTGAGTTCGGTCAGCG-3'). Neither of the two random oligodeoxynucleotides is complementary to any other known sequence. All oligodeoxynucleotides consisted of S-oligodeoxynucleotides, in which the phosphodiester backbone of the nucleotide was modified by the inclusion of a phosphorothioate to increase the resistance of the nucleotide to degradation by endogenous nucleases (Agrawal et al., 1991; Sklarczyk and Kaczmarek, 1995). All AODNs were purchased from Oligos, Etc. (Wilsonville, OR).

Stimulating and recording. For acute recording experiments, rats were anesthetized with urethane (1.3 gm/kg, i.p.), the left femoral vein or a lateral tail vein was cannulated, and the rat was installed into a stereotaxic frame. Body temperature was maintained at 37 ± 1°C with a thermostatically controlled solid-state heating device. All wound edges and contact points between the animal and the stereotaxic frame were infiltrated with lidocaine ointment (5%) or solution (2%).

After removal of the scalp, a small burr hole was drilled overlying the neostriatum (1.0 mm anterior to bregma, 3.7 mm lateral to the midline) for the insertion of stimulating electrodes. Bipolar stimulating electrodes with a tip separation of ~150 µm and in vitro impedances of ~10 kOmega were formed from 100-µm-diameter enamel-coated stainless steel wires (California Fine Wire). After releasing some CSF by puncturing the atlanto-occipital membrane, stimulating electrodes were lowered 4.0 mm below the cortical surface and cemented in place with cyanoacrylate glue and dental cement. For recording, holes ~3.0 mm in diameter were drilled above the substantia nigra at coordinates 2.1 mm anterior to lambda and 2.0 mm lateral to the midline, and the infusion cannulae were carefully removed.

Recording electrodes were fabricated from 2.0 mm outer diameter capillary tubing (World Precision Instruments, Kwik-filr) on a Narishige PE-2 vertical pipette puller and possessed in vitro impedances of ~20 MOmega when filled with 2 M NaCl. The electrode impedance was lowered to between 4 and 10 MOmega by passing 500 msec 150 V direct current pulses (Grass stimulator, model S-48) through the electrode in vitro.

Constant current electrical stimuli were generated with a Winston A-65 timer/stimulator and SC-100 constant current stimulus isolators. Neostriatal stimuli consisted of monophasic square-wave pulses of 0.2-3.0 mA intensity and 100-500 µsec duration and were delivered at a rate of 0.67 Hz. The antidromic threshold current was defined as the minimum current sufficient to elicit antidromic responses on 100% of the trials on which a collision with a spontaneous spike did not occur (Tepper et al., 1984a). Single unit extracellular recordings were amplified with a Neurodata IR-183 preamplifier and displayed on a Tektronix 5113A storage oscilloscope. All data were recorded on magnetic tape for off-line analysis on a Macintosh IIfx computer with a National Instruments MIO16L multifunction board and custom-designed software.

DAergic neurons were identified by their extracellular waveforms, often characterized by a prominent notch in the initial positive phase and having a duration of 2-5 msec, slow spontaneous activity, and long latency antidromic responses evoked from neostriatum that consisted mostly of initial segment (IS) only spikes (Deniau et al., 1978; Guyenet and Aghajanian, 1978; Tepper et al., 1984a,b). The pattern of firing of each neuron was classified as pacemaker, random, or bursty based on the neuron's autocorrelation histogram. Neurons showing three or more peaks in the autocorrelogram were classified as pacemaker, those showing an initial peak followed by a decay to a steady state were classified as bursty, and the remainder as random (Tepper et al., 1995). The proportion of antidromic spikes evoked at the threshold current for each neuron that consisted of the full spike (initial segment plus somatodendritic components) was taken as an index of somatodendritic excitability (Trent and Tepper, 1991).

Inhibitory responses after striatal stimulation were analyzed by constructing peristimulus time histograms and cumulative sum histograms (CUSUMs) (Ellaway, 1977) generated from spike trains. Changes in the slope of CUSUMs were used to delineate the onset, offset, and duration of stimulus-evoked effects as described in detail by Tepper et al. (1995). The average firing rate during the interval so defined was calculated by dividing the average number of spikes per bin during this interval by the prestimulus baseline activity.

Apomorphine dose-response measurements. After the establishment of a stable baseline firing rate for at least 5 min, a dose of apomorphine HCl that was double the previous dose was injected intravenously every 2 min, starting with either 1 or 2 µg/kg. This was continued until complete inhibition of spontaneous activity was obtained, a cumulative dose of 2048 µg/kg was reached, or until the cell was lost. In some cases in which complete inhibition was obtained, haloperidol lactate (50-200 µg/kg, i.v.) was subsequently administered in an attempt to reverse the inhibition. In most cases, the effects of apomorphine were studied on only one cell per animal. However, in a few cases, dose-response experiments were conducted on two cells, one ipsilateral to the infused side and one on the contralateral side. In these cases, haloperidol was not administered to the first cell studied, and a minimum of 3 hr elapsed between the last injection of apomorphine for the first cell and the beginning of the collection of baseline data for the second neuron.

Autoradiography. For receptor autoradiography, animals were euthanized by overdose of urethane, and the brains were rapidly removed and either frozen in isopentane cooled with dry ice or placed in a -80°C freezer. Subsequently, 20 µm coronal sections were taken on a cryostat at -18°C, thaw-mounted on gelatin-subbed slides, and stored at -80°C. Immediately before beginning the labeling incubation, the sections were gradually brought to room temperature, preincubated for 30 min in 50 mM Tris-HCl buffer, pH 7.4, containing 120 mM NaCl, 2 mM CaCl2, 5 mM KCl, 1 mM MgCl2, and 0.001% ascorbic acid (for D2-class binding) or 20 mM 3-(N-morpholino)propanesulfonic acid, pH 7.2, containing 50 mM NaCl, 1 mM EDTA, 10 µM pargyline, and 0.1% ascorbic acid (for D3 binding), and then incubated for 60 min at 22°C in the same buffer containing 1.2 nM 3H-spiperone for D2-class binding or 3 nM 3H-7-OH-N,N-di-n-propyl-2-aminotetralin (7-OHDPAT) for D3 binding. Nonspecific D2-class binding was determined by incubation in the presence of 1 µM (+) flupentixol, and nonspecific D3 binding was determined in the presence of 1 µM eticlopride. Incubation was terminated by rinsing the slides twice for 5 min with ice-cold buffer. After washing, the slides were dipped quickly in ice-cold water and dried under a stream of cold air. For D1-class binding, the buffer, incubation, and exposure times were the same as for D2-class binding, except that 1 nM 3H-SCH23390 was used in place of 3H-spiperone. Slides were then placed in x-ray cassettes, together with [3H] microscales (Amersham), and exposed to Hyperfilm-[3H] (Amersham) for 2 weeks (for 3H-spiperone binding) or for 2 months (for 3H-7-OHDPAT binding) at 4°C. Average binding densities were determined with a computerized image analysis system (Microcomputer Imaging Device, Imaging Research, St. Catharine's, Ontario, Canada).

Histological analyses. At the end of the recording experiment, animals that were not used for autoradiographic determination of the extent of receptor knockdown were deeply anesthetized with urethane and perfused intracardially with 50 ml of saline followed by 250 ml of 4% paraformaldehyde. The brain was then removed and placed into fixative overnight. Frozen coronal sections (60-80 µm) through substantia nigra and neostriatum were cut and processed either for tyrosine hydroxylase (TH) immunocytochemistry using a primary antibody from Eugene Tech International (Allendale, NJ) and the ABC protocol from Vector Laboratories (Burlingame, CA) as described previously (Tepper et al., 1994) or stained with neutral red for verification of recording and stimulating sites.

Data analysis. There were five types of controls for the local AODN infusions: recordings from substantia nigra DAergic neurons ipsilateral to saline infusions, ipsilateral to D2 random AODN infusions, ipsilateral to D3 random AODN infusions, contralateral to infusion of AODNs, and from untreated control animals. Most parametric electrophysiological data were analyzed with ANOVA followed by Fisher's protected least significant difference (PLSD) post hoc test at the p < 0.05 level of significance. Numbers in the text are expressed as mean ± SEM. Because these initial ANOVAs showed no significant differences in any of the parameters measured among the five different control groups, they were pooled into a single control group to increase the power of the statistical analyses. The distribution of firing pattern was analyzed with the chi 2 test. Dose-response and rotation data were first analyzed with a repeated-measures ANOVA followed by a factorial ANOVA to determine specific differences among the different treatment groups by dose or day of treatment. ED50s were log-transformed before ANOVA because the raw data exhibited heterogeneity of variance. Binding data were analyzed with paired t tests.

RESULTS

Neuronal identification

This report is based on data obtained from 175 neurons recorded from 83 rats. All neurons selected for study were presumed to be substantia nigra DAergic neurons on the basis of long duration bi- or triphasic extracellularly recorded waveform (>2.0 msec); spontaneous firing rate between 0.7 and 10.7 spikes/sec; pacemaker, random, or bursty firing pattern; and location in the midbrain. Of these neurons, 91 (52%) could be driven antidromically from neostriatum with characteristics (antidromic latency range, 7.70-23.5 msec; mean latency, 14.18 ± 0.38 msec; 66.4 ± 3.1% of all antidromic action potentials consisting of initial segment-only spike) that identify them conclusively as DAergic neurons (Deniau et al., 1978; Guyenet and Aghajanian, 1978). Representative examples of antidromically identified nigrostriatal DAergic neurons from an untreated control rat, a D2 random AODN-, a D2 AODN-, and a D3 AODN-treated rat are shown in Figure 1.
Fig. 1. Representative antidromic responses of substantia nigra DAergic neurons to striatal stimulation. Each group consists of six consecutive stimulus deliveries recorded from an untreated control (A), ipsilateral to a 6 d infusion of a control oligodeoxynucleotide (B), ipsilateral to a 6 d infusion of D2 AODN (C), and ipsilateral to a 6 d infusion of D3 AODN (D). The majority of the antidromic action potentials consist of the initial segment spike only, but some consist of a full initial segment-somatodendritic spike (arrows). The antidromic nature of the responses is verified by collision (asterisks) with spontaneous action potentials in the fourth, fifth, third, and fourth traces in A, B, C, and D, respectively. Positivity is upward.
[View Larger Version of this Image (34K GIF file)]

Apomorphine dose-response

Administration of either the D2 or the D3 AODN for 3-6 d produced a marked attenuation in the ability of intravenously administered apomorphine to inhibit the spontaneous activity of nigral DAergic neurons. Representative examples of ratemeter recordings are shown in Figure 2. In cells recorded from untreated controls (Fig. 2A) or ipsilateral to control oligodeoxynucleotide infusions (Fig. 2B), sequential intravenous injections of apomorphine produced marked inhibition of firing of antidromically identified nigrostriatal DAergic neurons before eventually producing complete suppression of spontaneous activity, typically by the time the cumulative dose reached 16 µg/kg. This inhibition could be readily reversed by subsequent administration of haloperidol (50-200 µg/kg, i.v.), as shown in Figure 2A. In contrast, neurons ipsilateral to infusion of D2 (Fig. 2B) or D3 (Fig. 2C) AODN were far less susceptible to the inhibitory effects of apomorphine, and in some cases could not be completely inhibited even at a cumulative dose of 2048 µg/kg. Simultaneous infusion of both D2 and D3 AODN (Fig. 2D) produced an even greater attenuation of the inhibitory response to apomorphine. The dose-response curves illustrated in Figure 2E reveal that treatment with either AODN alone produced a dramatic shift to the right in the apomorphine dose-response relation, and that the effects of the D2 and D3 AODNs appeared to be additive (repeated measures F = 11.73; df = 3, 40; p < 0.05). Overall, the D2 AODN dose-response curve (p < 0.05), the D3 AODN dose-response curve (p < 0.05), and the D2 + D3 AODN dose-response curve (p < 0.05) were significantly different from the control dose-response curve. The D2 + D3 AODN dose-response curve also differed significantly from the D2 AODN curve (p < 0.05).
Fig. 2. Individual ratemeter records of representative nigrostriatal neurons recorded from an untreated control animal (A), ipsilateral to a 6 d infusion of D2 AODN (B), ipsilateral to a 6 d infusion of D3 AODN (C), and ipsilateral to a 6 d infusion of both D2 and D3 AODNs (D). Apomorphine was administered intravenously every 2 min as indicated by the arrows. In the untreated (A) neuron, apomorphine produced complete inhibition of firing after the 8 µg/kg dose, and the inhibition was completely reversed by haloperidol, 50 µg/kg, intravenously. In contrast, neurons treated with D2, D3, or D2 + D3 AODN showed little or no effect at 8 µg/kg apomorphine and could not be completely inhibited even at cumulative doses in excess of 2000 µg/kg. E, Dose-response curves comparing the inhibition of firing among nigrostriatal neurons recorded ipsilateral to saline, random oligodeoxynucleotide, or D2, D3, or D2 + D3 AODN infusion, or contralateral to D2 or D3 AODN infusion or in untreated control rats. Note that all of the control groups are nearly identical, whereas the AODN antisense curves are shifted markedly to the right. Error bars indicate SEM. Each point is the mean of measurements from 3-6 cells for each of the different control groups, and from 7-10 cells for the 6 d D2 AODN infusion, the D3 AODN infusions, and the combined D2 + D3 AODN infusions.
[View Larger Version of this Image (30K GIF file)]

ED50s were estimated from the dose-response data. In the control groups, this was straightforward because all neurons were eventually completely inhibited by apomorphine, usually by the time the 16 µg/kg dose was reached. However, in the AODN-treated groups, many of the neurons could not be inhibited below 50% of baseline firing, even after the highest dose of apomorphine (1024 µg/kg). For these neurons, the ED50 was computed by fitting a log-probit curve to the data points and extrapolating. This was required for 6 of 14 D2 AODN-treated neurons, 5 of 12 D3 AODN-treated neurons, and 4 of 8 neurons from animals treated with D2 + D3 AODN. The fact that so many AODN-treated neurons could not be completely inhibited, or even inhibited to 50% of baseline, generated considerable variability in their ED50 estimates, which resulted in very large SEMs. The values were: control = 10.05 ± 3.5 µg/kg; D2 AODN = 475.6 ± 253.3 µg/kg; D3 AODN = 341.2 ± 248 µg/kg; D2 + D3 AODN = 623.8 ± 297 µg/kg. The increased ED50s after AODN treatment were not attributable to increases in baseline firing rate (see below); there were no significant correlations between ED50 and baseline firing within any of the AODN treatment groups, or overall when the AODN groups were pooled. However, there was a significant correlation between firing rate and ED50 with the pooled control group when one outlier was eliminated (r = 0.62; F = 6.86; df = 1, 11; p < 0.05), as has been described previously (Tepper et al., 1982; White and Wang, 1984).

To begin to estimate the minimum time required for AODN treatment to cause a functional knockdown of DA autoreceptors, a number of rats were given supranigral D2 or D3 antisense infusions for 3 d and prepared for recording on the fourth day. The response of these rats to apomorphine was indistinguishable from that in rats that had been treated with the AODN for 6 d (data not shown). All other electrophysiological parameters (see below) were likewise identical in the 3 and 6 d treated groups. Therefore, in all subsequent data analyses, data from animals treated for 3 d and those treated for 6 d were pooled.

Striatal-evoked inhibitory responses

To determine whether the reduction of the inhibitory response to apomorphine induced by the D2 or D3 AODNs was specific to DAergic inhibitory responses rather than an attenuation of inhibitory responses in general, the responses of DAergic neurons to single-pulse stimulation of neostriatum (0.67 Hz; 100-500 µsec duration; 0.2-3 mA) were examined. Striatal stimulation typically produces inhibition in DAergic neurons (Tepper et al., 1990). DAergic neurons from AODN-treated animals displayed inhibitory responses to striatal stimulation that were indistinguishable from those in controls in terms of onset latency, duration, and magnitude of inhibition, as illustrated in Figure 3.
Fig. 3. Striatal-evoked inhibitory responses of nigrostriatal neurons are not affected by AODN treatment. A1,2,3, Representative peristimulus time histograms showing inhibitory effect of striatal stimulation (arrow at time 0) in neurons from an untreated control, ipsilateral to D2 AODN infusion, and ipsilateral to D3 AODN infusion, respectively (bin width, 2 msec; 200 stimulus presentations in each case). Onset latency and duration of inhibition were computed by fitting a straight line through the prestimulus portion of the CUSUM histogram and another through the region where the slope changes. The intersection of these two lines represents the time at which the firing rate changes. The offset of stimulus-driven effects is similarly calculated by fitting a third line to the remainder of the CUSUM histogram, and the intersection of this line segment with the second line segment is the point at which the effect is no longer detectable. The magnitude of the inhibition was calculated by dividing the mean number of spikes per bin for the entire inhibitory period by the prestimulus control and expressing the ratio as the percent basal firing rate. Neither the onset latency (B), duration (C), nor magnitude of striatal-evoked inhibition (D) was significantly altered by AODN treatment. Numbers in bars indicate number of cells tested. Error bars denote SEM.
[View Larger Version of this Image (38K GIF file)]

Spontaneous activity

Spontaneous activity was assessed by measuring spontaneous firing rate and calculating the coefficient of variation of the interspike interval. In addition, the pattern of firing for each neuron was categorized based on the autocorrelation histogram of the neuron, as described above. Neither D2, D3, nor D2 + D3 AODN significantly altered mean firing rate or the coefficient of variation of DAergic neurons, as shown in Figure 4, A and B. Similarly, the relative proportions of neurons firing in the pacemaker, random, or bursty modes were not affected by any antisense treatment, as shown in Figure 4C.
Fig. 4. Lack of effect of D2, D3, or D2 + D3 AODN treatment on the rate or pattern of spontaneous activity of DAergic neurons. Firing patterns were classified from autocorrelograms as described in the text. Numbers in bars indicate the number of neurons measured. Error bars denote SEM.
[View Larger Version of this Image (20K GIF file)]

Antidromic response properties

The neostriatal threshold stimulating current was used as an index of the excitability of the terminals of DAergic nigrostriatal neurons (Tepper et al., 1984a). The mean threshold current in AODN-treated neurons was significantly lower than in controls (F = 4.38; df = 3, 76; p < 0.05), indicating an increase in nigrostriatal terminal excitability. Post hoc tests revealed significantly lower thresholds in DAergic neurons from D2 AODN-treated, D3 AODN-treated, and D2 + D3 AODN-treated rats than in controls (PLSD; p < 0.05). In addition, the proportion of antidromic spikes that consisted of the full spike [IS plus somatodendritic (SD) component] was calculated for each neuron as an index of somatodendritic excitability (Matsuda and Jinnai, 1980; Trent and Tepper, 1991). A significantly higher proportion of antidromic responses of neurons from AODN-treated rats consisted of a full spike than in control neurons (F = 3.49; df = 3, 61; p < 0.05), indicating a depolarization and increase in excitability of the somatodendritic membrane. As with antidromic excitability measurements, this could be attributed to a significantly higher proportion of full spike responses in each of the three AODN-treated groups compared with controls (PLSD; p < 0.05 for each comparison). These data are illustrated in Figure 5.
Fig. 5. Effects of AODN treatment on terminal and somatodendritic excitability of nigrostriatal DAergic neurons. A, Minimum current necessary to activate an antidromic response on each noncollision trial (threshold) is significantly lowered by treatment with D2, D3, or D2 + D3 AODN, indicating an increase in terminal excitability. B, The proportion of antidromic responses at threshold that consists of the full, or initial segment and somatodendritic, spike components is significantly increased by D2, D3, or D2 + D3 AODN treatment, indicating increased somatodendritic excitability. Numbers in bars indicate the number of neurons measured. Error bars denote SEM. *, significantly different from control group at p < 0.05.
[View Larger Version of this Image (19K GIF file)]

Autoradiography

Quantitative autoradiography was performed on selected sections from brains after supranigral infusion of D2 AODN, D3 AODN, D2 + D3 AODN, and random oligo infusion. Representative autoradiograms are shown in Figure 6, and the quantitative analyses are summarized graphically in Figure 7. The specific binding of D2-class (3H-spiperone), D3 (3H-7-OHDPAT), and D1-class receptors (3H-SCH-23390) in the substantia nigra on the treated side was compared with that on the control side by averaging the binding density over the pars compacta on either side of selected sections and dividing the average for the treated side by that for the control side. The decrease in 3H-spiperone binding on the D2 AODN-treated side ranged from a low of 32.4% to a high of 76.1%. The mean decrease in 3H-spiperone binding was 48.9 ± 3.3% (t = 11.96; df = 1, 15; p < 0.05).
Fig. 6. Representative autoradiograms of D2-class (3H-spiperone), D3 (3H-7-OHDPAT), and D1-class (3H-SCH23390) receptor binding in substantia nigra and D2-class receptor binding in neostriatum after 6 d of infusion of AODNs into the left substantia nigra. A, Total D2-class binding in substantia nigra after infusion of D2 AODN into the left substantia nigra. B, Specific D2-class binding in substantia nigra pars compacta ipsilateral to the infusion is reduced to 51.5% compared with the contralateral side. C, Total D1-class binding in substantia nigra from a nearby section. D, Specific D1-class binding in substantia nigra (pars compacta plus pars reticulata) on the ipsilateral side is unchanged compared with the contralateral control side, demonstrating the receptor specificity of the D2 AODN knockdown. E, Total D3 binding after infusion of D2 AODN into left substantia nigra. There is no decrease in D3 binding after D2 AODN infusion, demonstrating the specificity of the D2 AODN. F, Total D3 binding after infusion of D3 AODN into the left substantia nigra. D3 binding is reduced to 50% of the contralateral control side. G, Total D2-class binding after infusion of D3 AODN into left substantia nigra. H, Specific D2-class binding is unchanged after D3 AODN. H, Total D2-class binding in neostriatum after infusion of D2 AODN into left substantia nigra. J, Specific D2-class binding in neostriatum shows no significant change ipsilateral to the infusion, indicating that there is no retrograde knockdown after supranigral infusion of D2 AODN.
[View Larger Version of this Image (163K GIF file)]

Fig. 7. Mean effects of unilateral supranigral infusion of D2, D3, and D2 + D3 AODNs on DA receptor binding in substantia nigra and neostriatum. D2-class binding estimated from specific 3H-spiperone binding and D3 binding estimated from 3H-7-OHDPAT binding. A, Random oligodeoxynucleotides do not affect either D2-class or D3 receptor binding. D2 AODN specifically reduces D2-class binding without affecting D3 binding, whereas D3 AODN reduces D3 binding without significantly affecting D2-class binding. Combined administration of D2 and D3 AODNs produces reductions in D2-class and D3 binding similar to that seen when either AODN is administered alone. Control values for 3H-spiperone binding = 5.66 ± 0.4 nCi/mg; for 3H-7-OHDPAT binding = 1.22 ± 0.15 nCi/mg. B, Neither random oligodeoxynucleotides nor any of the AODNs infused supranigrally affect D1-class binding in substantia nigra estimated from 3H-SCH23390 binding. Control value for 3H-SCH23390 binding = 18.02 ± 0.82 nCi/mg. C, Neither random oligodeoxynucleotides nor any of the AODNs infused supranigrally affects D2-class (3H-spiperone) receptor binding in the ipsilateral neostriatum. Control value for 3H-spiperone binding in neostriatum = 12.02 ± 0.82 nCi/mg. Numbers in bars indicate number of neurons measured. Error bars denote SEM. *Significantly different from control group at p < 0.05.
[View Larger Version of this Image (28K GIF file)]

Although present at considerably lower levels than 3H-spiperone binding, 3H-7-OH-DPAT binding clearly demonstrated the presence of D3 receptors in the substantia nigra (Fig. 6E,F). Because the nonspecific binding of 3H-7-OH-DPAT was so low, the measurement of the change in D3 binding was made on total binding for 3H-7-OH-DPAT rather than on specific binding, as was the case for 3H-spiperone and 3H-SCH-23390 binding, both of which showed considerable nonspecific binding. There was no significant decrease in 3H-7-OH-DPAT binding after D2 AODN treatment (see Fig. 6E). Conversely, D3 AODN did not significantly decrease 3H-spiperone binding in substantia nigra (-4.3 ± 2.8%; see Fig. 6G,H) but did decrease 3H-7-OH-DPAT binding by 44.6 ± 5.8% (t = 7.17; df = 1, 12; p < 0.05; see Fig. 6F). Combined treatment with D2 and D3 AODNs decreased 3H-spiperone binding by 56.2 + 4.7% (t = 11.06; df = 1, 11; p < 0.05) and 3H-7-OH-DPAT binding by 49.8 + 6.2% (t = 7.53; df = 1, 11; p < 0.05). In contrast, there was no appreciable change in D1-class (3H-SCH23390) binding in substantia nigra after D2, D3, or combined D2 + D3 AODN infusion. Thus, the effects of the D2 and D3 AODNs were specific to the receptors for which they were designed, and were localized to the substantia nigra and immediately surrounding regions on the ipsilateral side.

There was apparently no retrograde transport of the D2 AODN back to the neostriatum with subsequent postsynaptic receptor loss after supranigral infusion of DA receptor AODNs, because 3H-spiperone binding in the neostriatum did not differ significantly between the control and treated sides, despite the large differences that were seen in substantia nigra (Fig. 6I,J).

Tyrosine hydroxylase immunocytochemistry

To determine whether the electrophysiological changes seen after AODN infusion could be attributable to nonspecific toxic effects on DAergic neurons, DAergic neurons in the ventral mesencephalon were visualized directly by TH immunocytochemistry. As can be seen in Figure 8, after a 6 d infusion of D2 AODN, there was no apparent loss of TH immunoreactive neurons ipsilateral to the AODN infusion, demonstrating that the D2 AODN did not produce nonspecific damage to DAergic neurons. Although no attempt was made to quantify these data, it is interesting that the DAergic neurons ipsilateral to the infusion appear to stain more intensely than those on the contralateral side.
Fig. 8. Effects of unilateral supranigral D2 AODN infusion on TH immunoreactivity in substantia nigra. A, Sixty micrometer coronal section through the midbrain of an animal in which 10 µg/µl D2 AODN was infused above the left substantia nigra for 6 d. The pale area marked by the asterisk is a small, nonspecific lesion made by the infusion cannula. Note that there is no apparent damage to DAergic (TH-immunopositive) substantia nigra neurons ipsilateral to the infusion. If anything, the density of TH immunostaining appears greater on the infused side. B, Sixty micrometer coronal section 180 µm posterior to that shown in A. An increased density of TH immunostaining is still apparent on the infused (left) side. C, D, Higher magnification photomicrographs through the central region of pars compacta ipsilateral (C) and contralateral (D) to D2 AODN infusion. Although the cell bodies also appear darker, the increased dendritic staining on the treated side is particularly noticeable.
[View Larger Version of this Image (121K GIF file)]

Behavioral observations during AODN treatment

The behavior of rats receiving unilateral intranigral infusion of D2 and/or D3 AODN was, for the most part, unremarkable. However, AODN-treated rats exhibited a modest contralateral postural deviation during rest, and intermittent or continuous spontaneous contralateral rotations at a relatively low rate, as shown in Figure 9. Both the contralateral postural deviation and the spontaneous contralateral rotation were evident by 24 hr after the start of the infusion, and became maximal after 3 d of infusion. Repeated measures ANOVA revealed a significant increase in rotations among both AODN-treated groups (F = 6.10; df = 3, 26; p < 0.05). A subsequent factorial ANOVA revealed that all treated groups differed from the random oligodeoxynucleotide-treated controls on all days of treatment (p < 0.05), and that the combined D2 + D3 AODN-treated group also differed significantly (p < 0.05) from either the D2 AODN-treated or the D3 AODN-treated groups on days 2, 3, and 5, suggesting an additivity in the effects of D2 and D3 receptor knockdown on spontaneous rotation. These asymmetric postural and locomotor behaviors were never observed in either saline- or random oligodeoxynucleotide-infused rats, and suggest an increased DA release in the ipsilateral striatum as a result of D2 and/or D3 autoreceptor knockdown. When challenged with the DA agonist apomorphine, no additional rotational behavior was induced in these rats, but the postural and locomotor asymmetries were almost completely abolished, as shown in Figure 9B.
Fig. 9. A, Spontaneous contralateral rotational behavior induced by unilateral supranigral infusion of 10 µg/µl D2, D3, random oligodeoxynucleotide (control), or D2 + D3 (20 µg/µl total) AODN (100 nl/hr). Each point represents the mean of two daily 30 min measurement periods from 9 to 16 animals. Error bars represent SEM. *Significantly different from control group at p < 0.05; dagger , significantly different from control and from D2 AODN-treated group at p < 0.05; §, significantly different from control and D3 AODN-treated group at p < 0.05; Dagger , significantly different from controls and from D2 and D3 AODN-treated group at p < 0.05. B, Challenge with apomorphine (1 mg/kg, i.p.) reduces rotational behavior in each of the treated groups. Data from 3- and 6-d treated rats combined; preinjection (pre) data taken from -60 to 0 min before injection and postinjection (post) data from 5 to 65 min after injection. *Significantly different from respective preinjection control.
[View Larger Version of this Image (20K GIF file)]

DISCUSSION

Specificity and extent of in vivo DA receptor AODN knockdown

The autoradiographic data demonstrate that the receptor knockdown produced by local infusion of DA receptor AODNs into the brain is relatively localized around the infusion site on the ipsilateral side. This is consistent with data showing that the maximal spread of an S-oligodeoxynucleotide of similar size injected intracerebrally was between 0.7 and 1.3 mm (Sklarczyk and Kaczmarek, 1995). Furthermore, D2 AODN reduced specifically 3H-spiperone (D2) binding in the substantia nigra without affecting D3 binding, and D3 AODN reduced specifically 3H-7OH DPAT (D3) binding without affecting D2 binding.

Supranigral infusion of D2 receptor AODN did not affect striatal 3H-spiperone binding. This observation is particularly important because it indicates that there is no retrograde knockdown of DA receptors. This is presumably because there is no uptake of the AODNs by striatonigral nerve terminals in substantia nigra. Thus, local infusion of AODNs can be used to selectively inactivate presynaptic or postsynaptic DA receptors, something that has not been possible by the use of conventional receptor antagonists or transgenic knockouts.

The maximal extent of the receptor loss, estimated from autoradiography, was always less than 100%. However, because the pars compacta is a relatively poorly defined structure and because the areas included in the autoradiographic comparisons unavoidably contained regions of low DA receptor density, averaging over the entire pars compacta would tend to underestimate the maximal knockdown in the most affected areas. In addition, 3H-spiperone can also label D3 receptors (Sokoloff et al., 1990; Bouthenet et al., 1991). D2 AODN does not affect D3 binding, and thus some of the residual 3H-spiperone binding after D2 AODN infusion is likely attributable to D3 receptors. Finally, because there is no retrograde uptake of D2 AODN, any D2-class receptors that may exist on nigral afferents would also be unaffected, and might contribute to the remaining 3H-spiperone binding. Thus, it is difficult to specify the upper limit of the knockdown potential of AODNs infused into the brain, but our data suggest that in the best cases there is an extensive reduction in DA receptors.

There were no obvious toxic effects of D2 AODN. The substantia nigra on the infused side appeared indistinguishable from its contralateral control in Nissl-stained sections, and TH immunocytochemistry failed to reveal any loss of DAergic neurons. Indeed, if there was any difference at all, the TH immunostaining appeared to be darker on the treated side than on the contralateral control. This may reflect a disinhibition of TH synthesis caused by the loss of D2 somatodendritic autoreceptors (Gauda and Gerfen, 1995).

Effects of DA receptor AODN treatment on apomorphine-induced inhibition of firing

Treatment with D2 or D3 AODN produced equivalent shifts to the right in the apomorphine dose-response curve. Combined treatment with both AODNs produced a significantly greater attenuation of the inhibitory effect of apomorphine. Although there was significant variability in the degree of attenuation, it is important that virtually all of the cells that were treated with either D2 or D3 AODN exhibited significantly less inhibition than control neurons. Thus, the variability did not arise because some neurons were essentially unaffected by D2 or D3 AODN treatment while others showed a near-complete blockade of apomorphine inhibition to one or the other AODN, which would suggest that some DA neurons express only D2 receptors, whereas others express only D3 receptors. Rather, the data suggest that virtually all neurons tested expressed both D2 and D3 somatodendritic autoreceptors.

The inhibition of nigrostriatal neurons in response to systemic administration of apomorphine at low doses has been shown to be attributable to a local action on somatodendritic autoreceptors (Akaoka et al., 1992; Pucak and Grace, 1994). Although it has long been known that DAergic neurons possess an autoreceptor of the D2 family (Groves et al., 1975; Aghajanian and Bunney, 1977; Lacey et al., 1987), these data provide direct electrophysiological evidence that DAergic neurons express both D2 and D3 somatodendritic autoreceptors, and that both participate in the inhibition of firing caused by DA agonists.

The decrease in spontaneous activity after administration of higher doses of apomorphine that persisted in many neurons from D2 or D3 AODN-treated animals could have resulted from incomplete knockdown of D2 or D3 autoreceptors. However, some of the inhibition resulting from systemic administration of other DAergic agonists (e.g., amphetamine) results from effects on forebrain structures (Bunney and Aghajanian, 1978; Sasaki et al., 1990), and whereas low doses of apomorphine (<16 µg/kg, i.v.) affect only DAergic neurons, higher doses can affect neostriatal neurons (Skirboll et al., 1979). Thus, it may be that a significant component of the inhibition that persists at high doses after AODN treatment is attributable to long-loop postsynaptic effects rather than local autoreceptor stimulation.

Time course of DA receptor AODN knockdown

Neither the apomorphine dose-response curves nor any of the other electrophysiological properties of DAergic neurons differed between animals treated with D2 AODN for 3 or 6 d, suggesting that the functional knockdown is near maximal by 3 d. This is consistent with our observations that AODN-treated animals began to exhibit spontaneous rotation after only 24 hr of treatment that reached a maximum at 3 d. Previous studies of the rate of DA receptor turnover based on the recovery of 3H-spiperone binding after irreversible receptor alkylation showed that the estimated t1/2 for D2-class receptor turnover depends on a number of factors, including age, DA content, and the precise methods used to inactivate the receptors (McKernan and Campbell, 1982; Hall et al., 1983; Leff et al., 1984; Norman et al., 1987), and can range from 8 hr to more than 6 d. Our electrophysiological and behavioral data favor the lower range of these turnover estimates.

Effects of DA receptor AODN treatment on spontaneous activity and somatodendritic excitability

Despite the marked effects of D2 and/or D3 AODN on the inhibition produced by apomorphine, neither AODN altered the spontaneous firing rate or pattern of nigrostriatal neurons. It is possible that compensatory changes in DAergic neurons or in their afferents masked the increase in spontaneous firing rate that would be predicted on the basis of the self-inhibition hypothesis. However, this explanation seems unlikely because of the rather short times involved (3 d) and because other related properties, including the response to apomorphine and the terminal and somatodendritic excitability, were markedly altered.

Changes in antidromic invasion of the somatodendritic region seen in extracellular recordings have been shown to correspond to changes in the level of membrane polarization of the somatodendritic region (Matsuda and Jinnai, 1980). Using this as an index of somatodendritic excitability, we have proposed previously that the physiological role of DAergic somatodendritic autoreceptors is more subtle than that of directly controlling the firing rate of the neuron as a whole (Trent and Tepper, 1991). In the present study, although D2 and/or D3 knockdown failed to increase the firing rate, the proportion of striatal-evoked antidromic responses that consisted of IS-SD spikes more than doubled. This was not attributable to the decreased threshold current in the treated cells (which might lead to a decrease in orthodromic inhibition from striatum and hence increase the excitability of the somatodendritic region; see Grace and Bunney, 1985; Grace, 1987; Trent and Tepper, 1991), because there was no correlation between the IS-SD percentage and the antidromic threshold current within any treatment group. Rather, the change appears attributable to a reduction in a tonic depression of somatodendritic excitability mediated by D2 and D3 autoreceptors interacting with endogenous DA. These data provide another example of an uncoupling of events in the somatodendritic and initial segment regions of the DAergic neuron (Grace, 1990; Hausser et al., 1995) and reinforce our previous suggestion (Trent and Tepper, 1990) that, at least in anesthetized rats, somatodendritic autoreceptors may not function to control the overall firing rate of the cell directly, but rather function to modulate somatodendritic excitability in a more subtle and local way.

Effects of DA receptor AODN treatment on antidromic thresholds

Axon terminal autoreceptors have been shown to modulate the stimulus-evoked release of DA in a number of different paradigms in vitro and in vivo (for review, see Starke et al., 1989). The threshold current has been used as an index of the excitability of DAergic nerve terminals and has been shown to vary depending on the extent of terminal autoreceptor stimulation; autoreceptor antagonists reduce the threshold current, whereas autoreceptor agonists increase threshold (Tepper et al., 1984a,b, 1987). In the present experiments, threshold currents of nigrostriatal neurons that were recorded ipsilateral to nigral infusion of D2 or D3 AODN were significantly lower than those in controls, demonstrating that DAergic neurons possess both functional D2 and D3 autoreceptors at the axon terminals, as well as in the somatodendritic region. The identification of a D2 terminal autoreceptor is consistent with a previous study using D2 AODN knockdown (Silvia et al., 1994), and the finding that there is also a D3 terminal autoreceptor is consistent with claims from biochemical studies (Meller et al., 1993; Nissbrandt et al., 1995). In vivo, terminal autoreceptors are sufficiently occupied by endogenous DA that administration of antagonists (Tepper et al., 1984a) or AODN knockdown significantly decreases the inhibitory tone on the terminal, resulting in increased terminal excitability and, presumably, increased DA release. It is likely this effect that is responsible for the spontaneous contralateral rotation observed during AODN treatment. These data also demonstrate that it is possible to knock out receptors on axon terminals of neurons that originate in the infusion site but extend several millimeters away.

Relative roles of D2 and D3 autoreceptors on substantia nigra neurons

The attenuating effects of D2 AODN on apomorphine-induced inhibition of nigrostriatal neurons and the increases in terminal and somatodendritic excitability were expected based on the large amount of D2 mRNA and D2-class binding present in substantia nigra. However, that D3 AODN was as effective as D2 AODN, and that the effects of D2 and D3 AODN treatment were additive were somewhat surprising given recent reports that there is only a low level of D3 mRNA present in the mesencephalon and that D3 mRNA was below detectable levels on many DAergic nigral neurons (Diaz et al., 1995). However, the difficulty in detecting D3 mRNA in the midbrain may simply reflect the relative overabundance of D2 mRNA and protein relative to that of D3 mRNA (Griffon et al., 1995). Our autoradiographic data suggest the presence of D3 binding in substantia nigra, albeit at relatively low levels. It may be that lower, but still physiologically functional, levels of D3 receptors are present on most or all mesencephalic DAergic neurons, but these are associated with lower levels of mRNA that require more sensitive PCR or related techniques for detection (Sokoloff et al., 1990; Valerio et al., 1994) and that are missed by in situ hybridization. A recent study using transfection of D2 and D3 receptors into a DAergic mesencephalic clonal line showed that D3 receptors were more than twice as potent at inhibiting DA release than D2 receptors, despite the fact that Bmax of the D2 receptors was three times greater than that of the D3 receptors (Tang et al., 1994), perhaps indicating that the receptor coupling mechanism(s) is more efficient for D3 receptors. Nevertheless, the fact that both D2 and D3 AODNs attenuated autoreceptor function at both the terminal and the somatodendritic regions of the neuron more or less equally suggests that the normal electrophysiological response attributed to somatodendritic and terminal autoreceptor stimulation may require coactivation of both D2 and D3 receptors.

Conclusion

In vivo knockdown of specific DA receptors by injection of AODNs into discrete brain regions is a valuable technique for assessing the functional roles and sites of action of different DA receptor subtypes for which selective ligands do not yet exist. The lack of retrograde knockdown suggests that this technique offers a method for selective inactivation of either pre- or postsynaptic receptors, something that has not previously been possible. The data presented here demonstrate that DAergic neurons possess functional D2 and D3 autoreceptors at both their axon terminal and somatodendritic regions. Both types of terminal autoreceptors modulate terminal excitability and presumably the release of DA from the nerve terminals and/or its synthesis, whereas somatodendritic D2 and D3 autoreceptors play a role in modulating the excitability of local dendritic regions.

FOOTNOTES

Received Nov. 27, 1996; revised Jan. 21, 1997; accepted Jan. 22, 1997.

  

This research was supported by the Johnson & Johnson Discovery Research Fund, the Hoechst-Celanese Innovative Research Award, and National Institute for Mental Health Grants MH-52450 and MH-52383. We thank Dr. Ming Zhang for work on the development of the D2 and D3 oligodeoxynucleotides and for assistance with the receptor autoradiography, Dr. P. Celada for help with the TH immunocytochemistry, L. Taylor for performing the ED50 calculations, and T. Koós for comments on this manuscript.

Correspondence should be addressed to Dr. James M. Tepper, Center for Molecular and Behavioral Neuroscience, Aidekman Research Center, Program in Cellular and Molecular Biodynamics, Rutgers University, University Heights, 197 University Avenue, Newark, NJ 07102.


REFERENCES

  • Aghajanian GK, Bunney BS (1977) Dopamine "autoreceptors:" pharmacological characterization by microiontophoretic single cell recording studies. Naunyn Schmiedebergs Arch Pharmacol 297:1-7 . [Web of Science][Medline]
  • Agrawal S, Temsamani J, Tang JY (1991) Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA 88:7595-7599 . [Abstract/Free Full Text]
  • Akaoka H, Charléty P, Saunier C-F, Buda M, Chouvet G (1992) Inhibition of nigral dopaminergic neurons by systemic and local apomorphine: possible contribution of dendritic autoreceptors. Neuroscience 49:879-892 . [Web of Science][Medline]
  • Bouthenet M-L, Souil E, Martres M-P, Sokoloff P, Giros B, Schwartz J-C (1991) Localization of dopamine D3 receptor mRNA in the rat using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res 564:203-219 . [Web of Science][Medline]
  • Boyar WC, Altar CA (1987) Modulation of in vivo dopamine release by D2 but not D1 receptor agonists and antagonists. J Neurochem 48:824-831 . [Web of Science][Medline]
  • Bunney BS, Aghajanian GK (1978) d-Amphetamine-induced depression of central dopamine neurons: evidence for mediation by both autoreceptors and a strio-nigral feedback pathway. Naunyn Schmiedebergs Arch Pharmacol 304:255-261 . [Web of Science][Medline]
  • Bunney BS, Walters JR, Roth RH, Aghajanian GK (1973) Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity. J Pharmacol Exp Ther 185:560-571 . [Abstract/Free Full Text]
  • Burris KD, Pacheco MA, Filtz TM, Kung M-P, Kung HF, Molinoff PB (1995) Lack of discrimination of agonists for D2 and D3 dopamine receptors. Neuropsychopharmacology 12:335-345 . [Web of Science][Medline]
  • Chesi AJR, Feasey-Truger KJ, Alzheimer C, ten Bruggencate G (1995) Dopamine autoreceptor sensitivity is unchanged in rat nucleus accumbens after chronic haloperidol treatment: an in vivo and in vitro voltametric study. Eur J Neurosci 7:2450-2457. [Web of Science][Medline]
  • Deniau JM, Hammond C, Riszk A, Feger J (1978) Electrophysiological properties of identified output neurons of the rat substantia nigra (pars compacta and pars reticulata): evidence for the existence of branched neurons. Exp Brain Res 32:409-422 . [Web of Science][Medline]
  • Diaz J, Lévesque D, Lammers CH, Griffon N, Martres M-P, Schwartz J-C, Sokoloff P (1995) Phenotypical characterization of neurons expressing the dopamine D3 receptor in the rat brain. Neuroscience 65:731-745 . [Web of Science][Medline]
  • Ellaway PH (1977) An application of the cumulative sum technique (cusums) to neurophysiology. J Physiol (Lond) 265:1-2.
  • Gauda EB, Gerfen CR (1995) Decrease in tyrosine hydroxylase mRNA expression in the carotid body during development: possible regulation by D2-dopamine autoreceptors. Soc Neurosci Abstr 21:854.
  • Gingrich JA, Caron MG (1993) Recent advances in the molecular biology of dopamine receptors. Annu Rev Neurosci 16:299-321 . [Web of Science][Medline]
  • Grace AA (1987) The regulation of dopamine neuron activity as determined by in vivo and in vitro intracellular recordings. In: neurophysiology of dopaminergic systems: current status and clinical perspectives (Chiodo LA, Freeman AS, eds), pp 1-66. Detroit: Lakeshore.
  • Grace AA (1990) Evidence for the functional compartmentalization of spike generating regions of rat midbrain dopamine neurons recorded in vitro. Brain Res 524:31-41 . [Web of Science][Medline]
  • Grace AA, Bunney BS (1985) Opposing effects of striatonigral feedback pathways on midbrain dopaminergic cell activity. Brain Res 333:271-284 . [Web of Science][Medline]
  • Griffon N, Diaz J, Lévesque D, Sautel F, Schwartz J-C, Sokoloff P, Simon P, Costentin J, Garrido F, Mann A, Wermuth C (1995) Localization, regulation, and role of the dopamine D3 receptor are distinct from those of the D2 receptor. Clin Neuropharmacol [Suppl 1] 18:S130-S142.
  • Groves PM, Wilson CJ, Young SJ, Rebec GV (1975) Self-inhibition by dopaminergic neurons. Science 190:522-529 . [Free Full Text]
  • Guyenet PG, Aghajanian GK (1978) Antidromic identification of dopaminergic and other output neurons of the rat substantia nigra. Brain Res 150:69-84 . [Web of Science][Medline]
  • Hall MD, Jenner P, Marsden CD (1983) Turnover of specific [3H]spiperone and [3H]N,n-propylnorapomorphine binding sites in rat striatum following phenoxybenzamine administration. Biochem Pharmacol 32:2937-2977.
  • Hausser M, Stuart G, Racca C, Sakmann B (1995) Axonal initiation and active dendritic propagation of action potentials in substantia nigra neurons. Neuron 15:637-647 . [Web of Science][Medline]
  • Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature (Lond) 277:93-96 . [Medline]
  • Kreiss DS, Bergstrom DA, Gonzalez AM, Huang K-X, Sibley DR, Walters JR (1995) Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities. Eur J Pharmacol 277:209-214 . [Web of Science][Medline]
  • Lacey MG, Mercuri NB, North RA (1987) Dopamine acts on D2 receptors to increase potassium conductance in neurones of the rat substantia nigra zona compacta. J Physiol (Lond) 392:397-416 . [Abstract/Free Full Text]
  • Leff SE, Gariano R, Creese I (1984) Dopamine receptor turnover rates are age-dependent. Proc Natl Acad Sci USA 81:3910-3914 . [Abstract/Free Full Text]
  • Lejeune F, Millan MJ (1995) Activation of dopamine D3 autoreceptors inhibits firing of ventral tegmental dopaminergic neurones in vivo. Eur J Pharmacol 275:R7-R9 . [Web of Science][Medline]
  • Le Moine C, Bloch B (1996) Expression of the D3 dopamine receptor in peptidergic neurons of the nucleus accumbens: comparison with the D1 and D2 dopamine receptors. Neuroscience 73:131-143 . [Web of Science][Medline]
  • Matsuda Y, Jinnai K (1980) Afferent inputs to caudate output neurons as monitored by antidromic spike invasion of the cell soma. Brain Res 188:560-565 . [Web of Science][Medline]
  • McKernan RM, Campbell IC (1982) Measurement of alpha adrenoceptor "turnover" using phenoxybenzamine. Eur J Pharmacol 80:279-280 . [Web of Science][Medline]
  • Meador-Woodruff JH, Mansour A, Healy DJ, Kuehn R, Zhou Q-Y, Bunzow JR, Akil H, Civelli O, Watson SJ (1991) Comparison of the distributions of D1 and D2 dopamine receptor mRNAs in rat brain. Neuropsychopharmacology 5:231-242 . [Web of Science][Medline]
  • Meller E, Bohmaker K, Goldstein M, Basham DA (1993) Evidence that striatal synthesis-inhibiting autoreceptors are dopamine D3 receptors. Eur J Pharmacol 249:R5-R6 . [Web of Science][Medline]
  • Morelli M, Mennini T, Di Chiara G (1988) Nigral dopamine autoreceptors are exclusively of the D2 type: quantitative autoradiography of [125I]iodosulpiride and [125I]SCH23892 in adjacent brain sections. Neuroscience 27:865-870 . [Web of Science][Medline]
  • Nissbrandt H, Ekman A, Eriksson E, Heilig M (1995) Dopamine D3 receptor antisense influences dopamine synthesis in rat brain. NeuroReport 6:573-576 . [Web of Science][Medline]
  • Norman AB, Battaglia G, Creese I (1987) Differential recovery rates of rat D2 dopamine receptors as a function of aging and chronic reserpine treatment following irreversible modification: a key to receptor regulatory mechanisms. J Neurosci 7:1484-1491 . [Abstract]
  • Pucak ML, Grace AA (1994) Evidence that systemically administered dopamine antagonists activate dopamine neuron firing primarily by blockade of somatodendritic autoreceptors. J Pharmacol Exp Ther 271:1181-1192 . [Abstract/Free Full Text]
  • Sasaki K, Suda H, Watanabe H, Yagi H (1990) Involvement of the entopeduncular nucleus and the habenula in methamphetamine-induced inhibition of dopamine neurons in the substantia nigra of rats. Brain Res Bull 25:121-127 . [Web of Science][Medline]
  • Seeman P, Van Tol HHM (1994) Dopamine receptor pharmacology. Trends Pharmacol Sci 15:264-270 . [Medline]
  • Sibley DR, Monsma Jr FJ (1992) Molecular biology of dopamine receptors. Trends Pharmacol Sci 13:61-69 . [Medline]
  • Silvia CP, King GR, Lee TH, Xue Z-Y, Caron MG, Ellinwood EH (1994) Intranigral administration of D2 dopamine receptor antisense oligodeoxynucleotides establishes a role for nigrostriatal D2 autoreceptors in the motor actions of cocaine. Mol Pharmacol 46:51-57 . [Abstract]
  • Skirboll LR, Grace AA, Bunney BS (1979) Dopamine auto- and postsynaptic receptors: electrophysiological evidence for differential sensitivity to dopamine agonists. Science 206:80-82 . [Abstract/Free Full Text]
  • Sklarczyk A, Kaczmarek L (1995) Antisense oligodeoxynucleotides: stability and distribution after intracerebral injection into rat brain. J Neurosci Methods 60:181-187. [Web of Science][Medline]
  • Sokoloff P, Giros B, Martres M-P, Bouthenet M-L, Schwartz J-C (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature (Lond) 347:146-151 . [Medline]
  • Starke K, Gothert M, Kilbinger H (1989) Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol Rev 69:864-989 . [Free Full Text]
  • Tang L, Todd RD, O'Malley KL (1994) Dopamine D2 and D3 receptors inhibit dopamine release. J Pharmacol Exp Ther 270:475-479 . [Abstract/Free Full Text]
  • Tepper JM, Nakamura S, Spanis CW, Squire LR, Young SJ, Groves PM (1982) Subsensitivity of catecholaminergic neurons to direct acting agonists after single or repeated electroconvulsive shock. Biol Psychiatry 17:1059-1070 . [Web of Science][Medline]
  • Tepper JM, Nakamura S, Young SJ, Groves PM (1984a) Autoreceptor-mediated changes in dopaminergic terminal excitability: effects of striatal drug infusions. Brain Res 309:317-333 . [Web of Science][Medline]
  • Tepper JM, Young SJ, Groves PM (1984b) Autoreceptor-mediated changes in dopaminergic terminal excitability: effects of increases in impulse flow. Brain Res 309:309-316 . [Web of Science][Medline]
  • Tepper JM, Gariano RF, Groves PM (1987) The neurophysiology of dopamine nerve terminal autoreceptors. In: Neurophysiology of dopaminergic systems: current status and clinical perspectives (Chiodo LA, Freeman AS, eds), pp 93-127. Grosse Point, MI: Lakeshore.
  • Tepper JM, Trent F, Nakamura S (1990) Postnatal development of the electrical activity of rat nigrostriatal dopaminergic neurons. Dev Brain Res 54:21-33 . [Medline]
  • Tepper JM, Damlama M, Trent F (1994) Postnatal changes in the distribution and morphology of rat substantia nigra dopaminergic neurons. Neuroscience 60:469-477 . [Web of Science][Medline]
  • Tepper JM, Martin LP, Anderson DR (1995) GABAA receptor-mediated inhibition of nigrostriatal dopaminergic neurons by pars reticulata projection neurons. J Neurosci 5:3092-3103.
  • Trent F, Tepper JM (1991) Dorsal raphé stimulation modifies striatal-evoked antidromic invasion of nigral dopaminergic neurons in vivo. Exp Brain Res 84:620-630 . [Web of Science][Medline]
  • Valerio A, Belloni M, Gorno ML, Tinti C, Memo M, Spano P (1994) Dopamine D2, D3, and D4 receptor mRNA levels in rat brain and pituitary during aging. Neurobiol Aging 15:713-719 . [Web of Science][Medline]
  • White FJ, Wang RY (1984) A10 dopamine neurons: role of autoreceptors in determining firing rate and sensitivity to dopamine agonists. Life Sci 34:1161-1170 . [Web of Science][Medline]
  • Wolf ME, Roth RH (1990) Autoreceptor regulation of dopamine synthesis. Ann NY Acad Sci 604:323-343 . [Web of Science][Medline]
  • Zhang M, Creese I (1993) Antisense oligodeoxynucleotide reduces brain dopamine D2 receptors: behavioral correlates. Neurosci Lett 161:223-226 . [Web of Science][Medline]
Copyright ©1997 Society for Neuroscience   0270-6474/1997/172519-12$05.00/0



This article has been cited by other articles:


Home page
 FASEB J.Home page
R. Zhao-Shea, B. N. Cohen, H. Just, T. McClure-Begley, P. Whiteaker, S. R. Grady, O. Salminen, P. D. Gardner, H. A. Lester, and A. R. Tapper
Dopamine D2-receptor activation elicits akinesia, rigidity, catalepsy, and tremor in mice expressing hypersensitive {alpha}4 nicotinic receptors via a cholinergic-dependent mechanism
FASEB J, January 1, 2010; 24(1): 49 - 57.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
D. H. Zald, R. L. Cowan, P. Riccardi, R. M. Baldwin, M. S. Ansari, R. Li, E. S. Shelby, C. E. Smith, M. McHugo, and R. M. Kessler
Midbrain Dopamine Receptor Availability Is Inversely Associated with Novelty-Seeking Traits in Humans
J. Neurosci., December 31, 2008; 28(53): 14372 - 14378.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Zapata, B. Kivell, Y. Han, J. A. Javitch, E. A. Bolan, D. Kuraguntla, V. Jaligam, M. Oz, L. D. Jayanthi, D. J. Samuvel, et al.
Regulation of Dopamine Transporter Function and Cell Surface Expression by D3 Dopamine Receptors
J. Biol. Chem., December 7, 2007; 282(49): 35842 - 35854.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
L. J. Gentet and S. R. Williams
Dopamine Gates Action Potential Backpropagation in Midbrain Dopaminergic Neurons
J. Neurosci., February 21, 2007; 27(8): 1892 - 1901.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
V. Davila, Z. Yan, L. C. Craciun, D. Logothetis, and D. Sulzer
D3 Dopamine Autoreceptors Do Not Activate G-Protein-Gated Inwardly Rectifying Potassium Channel Currents in Substantia Nigra Dopamine Neurons
J. Neurosci., July 2, 2003; 23(13): 5693 - 5697.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
Y. Schmitz, C. Schmauss, and D. Sulzer
Altered Dopamine Release and Uptake Kinetics in Mice Lacking D2 Receptors
J. Neurosci., September 15, 2002; 22(18): 8002 - 8009.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
A. Ricci, S. Marchal-Victorion, E. Bronzetti, A. Parini, F. Amenta, and S. K. Tayebati
Dopamine D4 Receptor Expression in Rat Kidney: Evidence for Pre- and Postjunctional Localization
J. Histochem. Cytochem., August 1, 2002; 50(8): 1091 - 1096.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
W. S. Cobb and E. D. Abercrombie
Distinct Roles for Nigral GABA and Glutamate Receptors in the Regulation of Dendritic Dopamine Release under Normal Conditions and in Response to Systemic Haloperidol
J. Neurosci., February 15, 2002; 22(4): 1407 - 1413.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. D. Stanwood, R. P. Artymyshyn, M.-P. Kung, H. F. Kung, I. Lucki, and P. McGonigle
Quantitative Autoradiographic Mapping of Rat Brain Dopamine D3 Binding with [125I]7-OH-PIPAT: Evidence for the Presence of D3 Receptors on Dopaminergic and Nondopaminergic Cell Bodies and Terminals
J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 1223 - 1231.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. Reavill, S. G. Taylor, M. D. Wood, T. Ashmeade, N. E. Austin, K. Y. Avenell, I. Boyfield, C. L. Branch, J. Cilia, M. C. Coldwell, et al.
Pharmacological Actions of a Novel, High-Affinity, and Selective Human Dopamine D3 Receptor Antagonist, SB-277011-A
J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 1154 - 1165.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. R. Ashby Jr., Y. Minabe, G. Stemp, J. J. Hagan, and D. N. Middlemiss
Acute and Chronic Administration of the Selective D3 Receptor Antagonist SB-277011-A Alters Activity of Midbrain Dopamine Neurons in Rats: An In Vivo Electrophysiological Study
J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 1166 - 1174.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. J. Millan, A. Gobert, A. Newman-Tancredi, F. Lejeune, D. Cussac, J.-M. Rivet, V. Audinot, T. Dubuffet, and G. Lavielle
S33084, a Novel, Potent, Selective, and Competitive Antagonist at Dopamine D3-Receptors: I. Receptorial, Electrophysiological and Neurochemical Profile Compared with GR218,231 and L741,626
J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 1048 - 1062.
[Abstract] [Full Text]

Home page
 J PsychopharmacolHome page
M. J. Millan, F. Lejeune, and A. Gobert
Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents
J Psychopharmacol, March 1, 2000; 14(2): 114 - 138.
[Abstract] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. J. Millan, A. Gobert, A. Newman-Tancredi, F. Lejeune, D. Cussac, J.-M. Rivet, V. Audinot, A. Adhumeau, M. Brocco, J.-P. Nicolas, et al.
S18327 (1-{2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperid-1-yl]ethyl}3-phenyl imidazolin-2-one), a Novel, Potential Antipsychotic Displaying Marked Antagonist Properties at alpha 1- and alpha 2-Adrenergic Receptors: I. Receptorial, Neurochemical, and Electrophysiological Profile
J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 38 - 53.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
Z. D. Ling, H. C. Robie, C. W. Tong, and P. M. Carvey
Both the Antioxidant and D3 Agonist Actions of Pramipexole Mediate Its Neuroprotective Actions in Mesencephalic Cultures
J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 202 - 210.
[Abstract] [Full Text]

Home page
 J. Neurosci.Home page
E. V. Kuzhikandathil and G. S. Oxford
Activation of Human D3 Dopamine Receptor Inhibits P/Q-Type Calcium Channels and Secretory Activity in AtT-20 Cells
J. Neurosci., March 1, 1999; 19(5): 1698 - 1707.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. J. Millan, A. Newman-Tancredi, M. Brocco, A. Gobert, F. Lejeune, V. Audinot, J.-M. Rivet, R. Schreiber, A. Dekeyne, M. Spedding, et al.
S 18126 ({2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl}), a Potent, Selective and Competitive Antagonist at Dopamine D4 Receptors: An In Vitro and In Vivo Comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2,3b]pyridine) and Raclopride
J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 167 - 186.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
V. Audinot, A. Newman-Tancredi, A. Gobert, J.-M. Rivet, M. Brocco, F. Lejeune, L. Gluck, I. Desposte, K. Bervoets, A. Dekeyne, et al.
A Comparative In Vitro and In Vivo Pharmacological Characterization of the Novel Dopamine D3 Receptor Antagonists (+)-S 14297, Nafadotride, GR 103,691 and U 99194
J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 187 - 197.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. J. Millan, A. Gobert, A. Newman-Tancredi, V. Audinot, F. Lejeune, J.-M. Rivet, D. Cussac, J.-P. Nicolas, O. Muller, and G. Lavielle
S 16924 ((R)-2-{1-[2-(2,3-Dihydro-Benzo[1,4] Dioxin-5-Yloxy)-Ethyl]-Pyrrolidin-3yl}-1-(4-Fluoro-Phenyl)-Ethanone), a Novel, Potential Antipsychotic with Marked Serotonin (5-HT)1A Agonist Properties: I. Receptorial and Neurochemical Profile in Comparison with Clozapine and Haloperidol
J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1341 - 1355.
[Abstract] [Full Text]

Home page
 J. Neurosci.Home page
T. E. Koeltzow, M. Xu, D. C. Cooper, X.-T. Hu, S. Tonegawa, M. E. Wolf, and F. J. White
Alterations in Dopamine Release But Not Dopamine Autoreceptor Function in Dopamine D3 Receptor Mutant Mice
J. Neurosci., March 15, 1998; 18(6): 2231 - 2238.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (92)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tepper, J. M.
Right arrow Articles by Creese, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tepper, J. M.
Right arrow Articles by Creese, I.

-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help
-
Copyright 2010 by Society for Neuroscience ONLINE ISSN: 1529-2401
-